With an aging baby boomer population, Alzheimer’s disease is reaching epidemic proportions within the US, afflicting 5.5 million Americans in 2018. This number is projected to double over the next 10 years*
- Virtually everybody has been touched by this disease through family or friends.
- Afflicting 1 in 9 Americans aged 65+*.
- 6th leading cause of death in America*.
- 1 in 3 seniors die with Alzheimer’s or other dementia*.
- 200,000 individuals under the age of 65 have young-onset of AD.
- No effective cure to date.
The New Therapy Toward the Cure for Alzheimer's Disease
- Human neural stem cells (HNSCs) existing within the brain will differentiate into functional neurons, astrocytes, or glial cells. When glial cells are activated in excess, plaques will form in the brain promoting the onset of Alzheimer’s disease.
- The overriding objective in the treatment of Alzheimer’s disease is to increase the number of fully functional neurons, while reducing the level of inflamation.
- The basic premise of SynapCyte’s revolutionary treatment (APC-100) directs or “biases” a patient’s existing neural stem cells toward development into new functional neurons rather than glial cells, while stimulating the proliferation of new neural stem cells.
SynapCyte researchers along with physicians from the College of Medicine, University of Central Florida believe they have the world’s first effective treatment to reverse the loss of brain function in Alzheimer’s disease patients.
Research using APC-100 injected into the Alzheimer’s disease model mice have demonstrated very impressive results in proliferation of neural stem cells generating new functional neurons.